Evogene Ltd. filed a Report of Foreign Private Issuer on November 10, 2026, disclosing the results of a special general meeting at which shareholders approved three proposals, including a Cooperation Agreement with L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., and confirmed the composition of a seven-member board of directors.

Key Highlights

  • Special meeting held: Evogene convened a special general meeting of shareholders on November 10, 2026, at its offices in Rehovot, Israel.
  • All three proposals approved: Proposals Nos. 1-3 were approved by the requisite vote of the Company's shareholders.
  • Cooperation Agreement effective: The agreement between L.I.A. Pure Capital Ltd., Invest-Pro Shukai Hon Ltd., and the Company became effective at the close of the meeting.
  • Seven-member board confirmed: The board is now comprised of Nir Nimrodi, Leon Y. Recanati, Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok, and Ofer Haviv.
  • Ofer Haviv remains President and CEO: Haviv, the Company's President and Chief Executive Officer, is included among the seven board members and signed the filing.

Evogene Special Meeting Outcomes and Board Reconstitution

Evogene Ltd. (NASDAQ:EVGN), an Israel-based agricultural biotechnology company, reported the outcome of a special general meeting held at its Park Rehovot offices on November 10, 2026. According to the filing, the meeting's agenda was drawn from the proxy statement that the Company attached as Exhibit 99.1 to an earlier Form 6-K furnished to the SEC on October 6, 2026. The filing states that all three proposals put to shareholders at the meeting received the requisite approval.

The filing discloses that a Cooperation Agreement between L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd. on one side, and the Company on the other, was approved at the meeting and became effective immediately upon its conclusion. Following that approval, the Company's board of directors was reconstituted and is now comprised of seven individuals: Nir Nimrodi, Leon Y. Recanati, Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok, and Ofer Haviv, who also serves as the Company's President and CEO. The filing was signed by Haviv on November 10, 2026.

The Company also noted that the contents of this report are incorporated by reference into its registration statements on Form F-3 (SEC File Nos. 333-277565 and 333-294650) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197, and 333-294648), effective from the date of submission to the extent not superseded by subsequent filings. No financial results or forward-looking operational data were included in this disclosure.

What Was Disclosed

Evogene reported that its shareholders approved all three proposals at a November 10, 2026 special general meeting, ratified a Cooperation Agreement with two external parties, and confirmed a seven-member board of directors including President and CEO Ofer Haviv.